TY - JOUR
T1 - Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy
T2 - Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
AU - Sugano, Kentaro
AU - Kontani, Teiji
AU - Katsuo, Shinichi
AU - Takei, Yoshinori
AU - Sakaki, Nobuhiro
AU - Ashida, Kiyoshi
AU - Mizokami, Yuji
AU - Asaka, Masahiro
AU - Matsui, Shigeyuki
AU - Kanto, Tatsuya
AU - Soen, Satoshi
AU - Takeuchi, Tsutomu
AU - Hiraishi, Hideyuki
AU - Hiramatsu, Naoki
N1 - Funding Information:
Grant support by Takeda Pharmaceutical Company Limited.
PY - 2012/5
Y1 - 2012/5
N2 - Background Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain. Methods This multi-center, prospective, double-blind, randomized, active-controlled study involving 99 sites in Japan was designed to compare the efficacy of lansoprazole (15 mg daily) with gefarnate (50 mg twice daily). Patients with a history of gastric or duodenal ulcers who required long-term NSAID therapy were randomized to receive lansoprazole 15 mg daily (n = 185) or gefarnate 50 mg twice daily (n = 181) and followed up for 12 months or longer prospectively. Results The cumulative incidence of gastric or duodenal ulcer at days 91, 181, and 361 from the start of the study was calculated by the Kaplan-Meier method as 3.3, 5.9, and 12.7%, respectively, in the lansoprazole group versus 18.7, 28.5, and 36.9%, respectively, in the gefarnate group. The risk for ulcer development was significantly (log-rank test, P<0.0001) lower in the lansoprazole group than in the gefarnate group, with the hazard ratio being 0.2510 (95% CI 0.1400-0.4499). A long-term follow-up study showed an acceptable safety profile for low-dose lansoprazole therapy, with diarrhea as the most frequent adverse event. Conclusion Lansoprazole was superior to gefarnate in reducing the risk of gastric or duodenal ulcer recurrence in patients with a definite history of gastric or duodenal ulcers who required long-term NSAID therapy.
AB - Background Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain. Methods This multi-center, prospective, double-blind, randomized, active-controlled study involving 99 sites in Japan was designed to compare the efficacy of lansoprazole (15 mg daily) with gefarnate (50 mg twice daily). Patients with a history of gastric or duodenal ulcers who required long-term NSAID therapy were randomized to receive lansoprazole 15 mg daily (n = 185) or gefarnate 50 mg twice daily (n = 181) and followed up for 12 months or longer prospectively. Results The cumulative incidence of gastric or duodenal ulcer at days 91, 181, and 361 from the start of the study was calculated by the Kaplan-Meier method as 3.3, 5.9, and 12.7%, respectively, in the lansoprazole group versus 18.7, 28.5, and 36.9%, respectively, in the gefarnate group. The risk for ulcer development was significantly (log-rank test, P<0.0001) lower in the lansoprazole group than in the gefarnate group, with the hazard ratio being 0.2510 (95% CI 0.1400-0.4499). A long-term follow-up study showed an acceptable safety profile for low-dose lansoprazole therapy, with diarrhea as the most frequent adverse event. Conclusion Lansoprazole was superior to gefarnate in reducing the risk of gastric or duodenal ulcer recurrence in patients with a definite history of gastric or duodenal ulcers who required long-term NSAID therapy.
KW - Active-controlled trial
KW - Gastric or duodenal ulcers
KW - Lansoprazole
KW - Non-steroidal anti-inflammatory drugs
KW - Osteoarthritis
KW - Prevention
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84862518762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862518762&partnerID=8YFLogxK
U2 - 10.1007/s00535-012-0541-z
DO - 10.1007/s00535-012-0541-z
M3 - Article
C2 - 22388884
AN - SCOPUS:84862518762
VL - 47
SP - 540
EP - 552
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
SN - 0944-1174
IS - 5
ER -